|Articles|January 29, 2006
Sustained-release formula in works for neovascular AMD
Advertisement
PR Pharmaceuticals Inc. (PRP) and OSI Pharmaceuticals entered an agreement to develop a sustained-release formula of pegaptanib sodium injection (Macugen), a novel treatment for neovascular age-related macular degeneration.
The agreement gives OSI and its development and marketing partner Pfizer access to PRP's proprietary ProPhase technology for encapsulating pegaptanib sodium injection for ophthalmic use. OSI's eye disease unit, Eyetech Pharmaceuticals, is responsible for clinical development activities and has the right to manufacture and commercialize the resulting product.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaucoma 2026: Which emerging technologies will change practice?
2
How AI is reshaping ophthalmology in 2025 and beyond
3
Molecular insights and clinical experience: Extending anti-VEGF durability
4
8 things to know about aflibercept 8 mg for retinal vascular disease
5








































